Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06100952 · ClinicalTrials.gov registry record · Phase 3
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age with Keratoconus
A Phase 3 study of Keratoconus, sponsored by Epion Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 12
- Study locations
NCT06100952 is a Phase 3 study of Keratoconus that is active but no longer recruiting, run by Epion Therapeutics. The registered enrollment target is 400 participants, below the 1,161-participant average among 21 other Keratoconus trials with a reported enrollment target (66% lower). The trial reports 12 study locations across 11 states.
The verdict
NCT06100952, a Phase 3 study of Keratoconus, is active but no longer recruiting, sponsored by Epion Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 12
- Study locations
Study Summary
A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
Conditions Studied
Interventions
- COMBINATION_PRODUCT Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment
- COMBINATION_PRODUCT Placebo and sham treatment
Study Locations (12)
Arizona
- Schwartz Laser Eye Center - Scottsdale
- Catalina Eye Center - Tucson
California
- Inland Eye Specialists - Murrieta
Colorado
- University of Colorado - Aurora
Illinois
- Chicago Cornea Consultants - Highland Park
Massachusetts
- Claris Vision LLC Eye Health Vision Centers - Dartmouth - North Dartmouth
Nebraska
- Truhlsen Eye Institute - Omaha
North Carolina
- Providence Eye and Laser Specialists - Charlotte
Tennessee
- VRF Eye Specialty Group - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2025-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06100952
The ClinicalTrials.gov registry entry for NCT06100952 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,161-participant average among 21 other Keratoconus trials with a reported enrollment target (66% lower). The listed sponsor is Epion Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Keratoconus appearing as the primary indexed condition, and to 2 interventions - of which Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment is the first listed.
NCT06100952 reports 12 study locations spanning 11 distinct geographic areas - top geographies include Arizona, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06100952 about?
NCT06100952 is a clinical study titled "Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age with Keratoconus". A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
What is the current status of trial NCT06100952?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2023-11-01. Estimated completion is 2025-11.
What conditions does trial NCT06100952 study?
This clinical trial studies the following conditions: Keratoconus.
What interventions are being tested in trial NCT06100952?
The interventions under investigation include: Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment (COMBINATION_PRODUCT), Placebo and sham treatment (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06100952?
This trial is sponsored by Epion Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06100952 being conducted?
This trial has 12 study locations across Arizona, California, Colorado, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratoconus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
RECRUITING · Phase 3
-
Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome
RECRUITING · Phase 3
-
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus
COMPLETED · Phase 3
-
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
RECRUITING
-
OCT in Diagnosis of Irregular Corneas
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.